FOR IMMEDIATE RELEASE
- Conference runs November 27–28 at the Hilton Bogotá Corferias, continuing ISSCA’s expansion of physician education throughout Latin America
- Program targets more than 250 physician attendees across flagship and peptide-medicine certification tracks
- Event complements Cellgenic’s parallel commercial expansion into Colombia
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 128, its conference in Bogotá, Colombia, taking place November 27–28 at the Hilton Bogotá Corferias.
The Bogotá conference continues ISSCA’s ongoing expansion of physician education throughout Latin America, with a program built around the organization’s flagship and peptide-medicine certification tracks. Confirmed faculty and full workshop programming will be published as the event date approaches.
The event runs alongside Cellgenic’s operational expansion into Colombia, reinforcing ISSCA and Cellgenic’s coordinated approach to entering new Latin American markets through both education and commercial channels.
“Bogotá gives ISSCA a direct connection to Colombia’s physician community right as Cellgenic is building out commercial operations there too,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “That kind of coordination is exactly the model we want to replicate.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
